DocDollars

Bioverativ Therapeutics Inc.

MA · United States · Reporting entity ID 100000181764

Total reported 2019–2025
$11.1M
#459 of 2,960 reporting companies — 0% of all reported industry payments
$4.38M in general payments across 1,032 records, plus $6.70M in research funding across 1,733 records.

How it breaks down

General payments $4,377,273
Research funding $6,702,493

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Bioverativ Therapeutics Inc. reported $11.1M to US doctors and teaching hospitals from 2019 to 2025, ranking #459 of 2,960 reporting companies. 60% of that was research funding and 40% general payments such as consulting, speaking, food and travel. 1,032 general payment records and 1,733 research records were filed.

Common questions about Bioverativ Therapeutics Inc.

How much has Bioverativ Therapeutics Inc. paid US doctors?

Bioverativ Therapeutics Inc. reported $11,079,765 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $4,377,273 in general payments, $6,702,493 in research funding.

How does Bioverativ Therapeutics Inc. rank among drug and device companies?

It ranks #459 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Bioverativ Therapeutics Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.